Cargando…

Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis

BACKGROUND: Human trichomoniasis caused by Trichomonas vaginalis is one of the most common sexually transmitted diseases with more than 200 million cases worldwide. It has caused a series of health problems to patients. For prevention and control of infectious diseases, vaccines are usually consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yi-Ting, Gao, Jiang-Mei, Wu, Ya-Ping, Tang, Petrus, Hide, Geoff, Lai, De-Hua, Lun, Zhao-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312525/
https://www.ncbi.nlm.nih.gov/pubmed/28209207
http://dx.doi.org/10.1186/s13071-017-2009-8
_version_ 1782508221066379264
author Xie, Yi-Ting
Gao, Jiang-Mei
Wu, Ya-Ping
Tang, Petrus
Hide, Geoff
Lai, De-Hua
Lun, Zhao-Rong
author_facet Xie, Yi-Ting
Gao, Jiang-Mei
Wu, Ya-Ping
Tang, Petrus
Hide, Geoff
Lai, De-Hua
Lun, Zhao-Rong
author_sort Xie, Yi-Ting
collection PubMed
description BACKGROUND: Human trichomoniasis caused by Trichomonas vaginalis is one of the most common sexually transmitted diseases with more than 200 million cases worldwide. It has caused a series of health problems to patients. For prevention and control of infectious diseases, vaccines are usually considered as one of the most cost-efficient tools. However, until now, work on the development of T. vaginalis vaccines is still mainly focused on the screening of potential immunogens. Alpha-actinin characterized by high immunogenicity in T. vaginalis was suggested as a promising candidate. Therefore, the purpose of this study was to evaluate the protective potency of recombinant α-actinin against T. vaginalis infection in a mouse intraperitoneal model. METHODS: Two selected coding regions of α-actinin (ACT-F, 14–469 aa and ACT-T, 462–844 aa) amplified from cDNA were cloned into pET-32a (+) expression vector and transfected into BL21 cells. After induction with IPTG and purification with electroelution, the two recombinant fusion proteins were emulsified in Freund’s adjuvant (FA) and used to immunize BALB/C mice. Following intraperitoneal inoculation with T. vaginalis, the survival rate of mice was monitored for the assessment of protective potency. After immunization, the antibody level in mouse serum was assessed by ELISA, splenocyte proliferation response was detected with CCK8 and cytokines in the supernatant of splenocytes were quantified with a cytometric bead-based assay. RESULTS: We successfully obtained purified ACT-F (70.33 kDa) and ACT-T (61.7kDa). Both recombinant proteins could provide significant protection against T. vaginalis challenge, especially ACT-T (with 100% protection within one month). Meanwhile, high levels of specific total IgG and subtypes (IgG1 > IgG2a) were detected in sera from the immunized mice. Our results also revealed a statistically significant increase in splenocyte proliferation and related cytokine (IFN-γ, IL-6, IL-17A and IL-10) production after repeated stimulation with the corresponding antigens in vitro. CONCLUSIONS: Immunization with both ACT-F and ACT-T could confer partial to complete protection and trigger strong Th1/Th2 mixed humoral and cellular immune responses in the mouse host. This suggested that recombinant α-actinin subunit antigens may be promising vaccine candidates against trichomoniasis.
format Online
Article
Text
id pubmed-5312525
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53125252017-02-24 Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis Xie, Yi-Ting Gao, Jiang-Mei Wu, Ya-Ping Tang, Petrus Hide, Geoff Lai, De-Hua Lun, Zhao-Rong Parasit Vectors Research BACKGROUND: Human trichomoniasis caused by Trichomonas vaginalis is one of the most common sexually transmitted diseases with more than 200 million cases worldwide. It has caused a series of health problems to patients. For prevention and control of infectious diseases, vaccines are usually considered as one of the most cost-efficient tools. However, until now, work on the development of T. vaginalis vaccines is still mainly focused on the screening of potential immunogens. Alpha-actinin characterized by high immunogenicity in T. vaginalis was suggested as a promising candidate. Therefore, the purpose of this study was to evaluate the protective potency of recombinant α-actinin against T. vaginalis infection in a mouse intraperitoneal model. METHODS: Two selected coding regions of α-actinin (ACT-F, 14–469 aa and ACT-T, 462–844 aa) amplified from cDNA were cloned into pET-32a (+) expression vector and transfected into BL21 cells. After induction with IPTG and purification with electroelution, the two recombinant fusion proteins were emulsified in Freund’s adjuvant (FA) and used to immunize BALB/C mice. Following intraperitoneal inoculation with T. vaginalis, the survival rate of mice was monitored for the assessment of protective potency. After immunization, the antibody level in mouse serum was assessed by ELISA, splenocyte proliferation response was detected with CCK8 and cytokines in the supernatant of splenocytes were quantified with a cytometric bead-based assay. RESULTS: We successfully obtained purified ACT-F (70.33 kDa) and ACT-T (61.7kDa). Both recombinant proteins could provide significant protection against T. vaginalis challenge, especially ACT-T (with 100% protection within one month). Meanwhile, high levels of specific total IgG and subtypes (IgG1 > IgG2a) were detected in sera from the immunized mice. Our results also revealed a statistically significant increase in splenocyte proliferation and related cytokine (IFN-γ, IL-6, IL-17A and IL-10) production after repeated stimulation with the corresponding antigens in vitro. CONCLUSIONS: Immunization with both ACT-F and ACT-T could confer partial to complete protection and trigger strong Th1/Th2 mixed humoral and cellular immune responses in the mouse host. This suggested that recombinant α-actinin subunit antigens may be promising vaccine candidates against trichomoniasis. BioMed Central 2017-02-16 /pmc/articles/PMC5312525/ /pubmed/28209207 http://dx.doi.org/10.1186/s13071-017-2009-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Xie, Yi-Ting
Gao, Jiang-Mei
Wu, Ya-Ping
Tang, Petrus
Hide, Geoff
Lai, De-Hua
Lun, Zhao-Rong
Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title_full Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title_fullStr Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title_full_unstemmed Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title_short Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
title_sort recombinant α-actinin subunit antigens of trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312525/
https://www.ncbi.nlm.nih.gov/pubmed/28209207
http://dx.doi.org/10.1186/s13071-017-2009-8
work_keys_str_mv AT xieyiting recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT gaojiangmei recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT wuyaping recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT tangpetrus recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT hidegeoff recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT laidehua recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis
AT lunzhaorong recombinantaactininsubunitantigensoftrichomonasvaginalisaspotentialvaccinecandidatesinprotectingagainsttrichomoniasis